Salix Pharmaceuticals Announces Plan to Augment Board of Directors
Salix Pharmaceuticals, Ltd. announced that it has engaged Russell Reynolds Associates to conduct a comprehensive search to assist the company in identifying experienced, highly qualified individuals to serve as independent members of the Company's Board of Directors.
RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) (“Salix” or the “Company”) announced that it has engaged Russell Reynolds Associates, a nationally recognized search firm, to conduct a comprehensive search to assist the Company in identifying experienced, highly qualified individuals to serve as independent members of the Company’s Board of Directors. The search process will seek to identify proven business leaders with complementary and relevant expertise to increase the depth, skillset and perspective of the Salix Board.
Tom D’Alonzo, Chairman of the Board of Directors, said, “We have been discussing for some time adding to the collective experience of our Board as Salix has grown rapidly into a market leader in gastroenterology. We are focused on bringing on board individuals with the highest credentials, including past service on public company boards of directors and significant specialty pharmaceuticals experience.”
Salix currently anticipates that it will complete its search and increase the size of its Board by adding new independent directors in the first quarter of 2015.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix’s strategy is to in-license or acquire late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and commercialize them through Salix’s 500-member specialty sales force.
Salix trades on the NASDAQ Global Select Market under the ticker symbol “SLXP”.
For more information, please visit Salix’s Website at www.salix.com or contact Salix at 919-862-1000. Follow Salix on Twitter (@SalixPharma) and Facebook (www.facebook.com/SalixPharma). Information on Salix’s Twitter feed, Facebook page and web site is not incorporated in Salix’s filings with the SEC.